Business Description
BioCardia Inc
NAICS : 325412
SIC : 2834
ISIN : US09060U6064
Total Employee Number:
21Description
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.31 | |||||
Equity-to-Asset | -0.62 | |||||
Debt-to-Equity | -0.39 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 50.2 | |||||
3-Year EPS without NRI Growth Rate | 50.4 | |||||
3-Year FCF Growth Rate | 50.1 | |||||
3-Year Book Growth Rate | -71.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 29.91 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 90.15 | |||||
9-Day RSI | 77.34 | |||||
14-Day RSI | 68.48 | |||||
3-1 Month Momentum % | -22.79 | |||||
6-1 Month Momentum % | -28.26 | |||||
12-1 Month Momentum % | -59.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.41 | |||||
Quick Ratio | 0.41 | |||||
Cash Ratio | 0.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -100.3 | |||||
Shareholder Yield % | -46.41 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -250.35 | |||||
ROIC % | -450.14 | |||||
3-Year ROIIC % | -233.59 | |||||
ROC (Joel Greenblatt) % | -1275.78 | |||||
ROCE % | -29613.64 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -2.22 | |||||
EV-to-Forward-EBIT | -1.65 | |||||
EV-to-EBITDA | -2.22 | |||||
EV-to-Forward-EBITDA | -1.65 | |||||
EV-to-Forward-Revenue | 262.74 | |||||
EV-to-FCF | -2.32 | |||||
Price-to-GF-Value | 24 | |||||
Earnings Yield (Greenblatt) % | -45.05 | |||||
FCF Yield % | -41.88 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BCDA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
BioCardia Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.034 | ||
| Beta | 1.2613 | ||
| 3-Year Sharpe Ratio | -0.82 | ||
| 3-Year Sortino Ratio | -1.04 | ||
| Volatility % | 43.8 | ||
| 14-Day RSI | 68.48 | ||
| 14-Day ATR ($) | 0.118627 | ||
| 20-Day SMA ($) | 0.938275 | ||
| 12-1 Month Momentum % | -59.14 | ||
| 52-Week Range ($) | 0.7765 - 2.45 | ||
| Shares Outstanding (Mil) | 14.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
BioCardia Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
BioCardia Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-02 09:00 | In 158 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-12 16:30 | In 138 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 137 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-11 16:30 | In 45 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 44 days | ||
| First quarter earnings conference call for 2026 | 2026-05-15 16:30 | 1.09 (+0.93%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 1.09 (+0.93%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-24 16:30 | 1.20 (+0.84%) | ||
| Annual report for 2025 | 2026-03-24 | 1.20 (+0.84%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-24 | 1.20 (+0.84%) |
Show
Entries
BioCardia Inc Frequently Asked Questions
What is BioCardia Inc(BCDA)'s stock price today?
The current price of BCDA is $1.20. The 52 week high of BCDA is $2.45 and 52 week low is $0.78.
When is next earnings date of BioCardia Inc(BCDA)?
The next earnings date of BioCardia Inc(BCDA) is 2026-08-11 Est..
Does BioCardia Inc(BCDA) pay dividends? If so, how much?
BioCardia Inc(BCDA) does not pay dividend.
Guru Commentaries on NAS:BCDA
No articles.
Press Release
Articles on BioCardia Inc
No articles.
Headlines
See More- 1
Jun 09, 2026
What's Going On With BioCardia Stock Tuesday?
Benzinga • 6:50am
Jun 05, 2026
Why Is BioCardia Stock Gaining Friday?
Benzinga • 10:06am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers